DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma

Ma,Jianjuan; Yu,Xiying; Guo,Liping; Lu,Shih  Hsin

doi:10.3892/ol.2013.1605

DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma

Authors:
- Jianjuan Ma
- Xiying Yu
- Liping Guo
- Shih Hsin Lu
View Affiliations

Affiliations: State Key Laboratory of Molecular Oncology and Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
Published online on: October 7, 2013 https://doi.org/10.3892/ol.2013.1605
Pages: 1624-1630

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dual‑specificity phosphatase 6 (DUSP6), a specific negative feedback regulator of phosphorylated extracellular signal‑regulated kinase, was found to play an important role in numerous types of solid tumors as a tumor suppressor. In this study, 64.2% (61/95) of esophageal squamous cell carcinoma (ESCC) specimens studied exhibited reduced DUSP6 protein expression, compared with 91% (81/89) of normal esophageal specimens that displayed moderate or strong DUSP6 protein expression in tissue microarray analysis. In total, 36.8% (7/19) of the tumor biopsies displayed at least two‑fold downregulation of DUSP6 compared with their paired normal counterparts, by qPCR. Significant loss of DUSP6 was observed in EC9706 and KYSE150 ESCC cell lines by immunoblotting assay. Low DUSP6 protein expression was significantly associated with pathological grade in ESCC by immunohistochemistry (P<0.05). Treatment with 5‑aza‑2'‑deoxycytidine restored DUSP6 expression in the two ESCC cell lines, and the expression varied according to the drug concentration. Methylation‑specific PCR analysis showed methylation‑specific products in the two ESCC cell lines. We observed significant differences in the early and total apoptotic proportion between the control and experimental groups of the two ESCC cell lines and their transfectants (P<0.001) by annexin/propidium iodide assay. The presence of cleaved PARP product, a marker of caspase‑mediated apoptosis, expressed in the two pCMV‑DUSP6 transfectants in marked contrast to the parental and pCMV‑transfected EC9706 and KYSE150 cells, was observed by immunoblotting. Overall, our results support the role of DUSP6 as a novel candidate tumor suppressor gene in ESCC, which may be a potential prognostic marker for ESCC.

View Figures

View References

1	Arkell RS, Dickinson RJ, Squires M, Hayat S, Keyse SM and Cook SJ: DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5. Cell Signal. 20:836–843. 2008. View Article : Google Scholar : PubMed/NCBI
2	Eblaghie MC, Lunn JS, Dickinson RJ, et al: Negative feedback regulation of FGF signaling levels by Pyst1/MKP3 in chick embryos. Curr Biol. 13:1009–1018. 2003. View Article : Google Scholar : PubMed/NCBI
3	Lewis TS, Shapiro PS and Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res. 74:49–139. 1998. View Article : Google Scholar : PubMed/NCBI
4	Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
5	Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
6	Ekerot M, Stavridis MP, Delavaine L, et al: Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem J. 412:287–298. 2008. View Article : Google Scholar : PubMed/NCBI
7	Nichols A, Camps M, Gillieron C, et al: Substrate recognition domains within extracellular signal-regulated kinase mediate binding and catalytic activation of mitogen-activated protein kinase phosphatase-3. J Biol Chem. 275:24613–24621. 2000. View Article : Google Scholar
8	Muda M, Theodosiou A, Gillieron C, et al: The mitogen-activated protein kinase phosphatase-3 N-terminal noncatalytic region is responsible for tight substrate binding and enzymatic specificity. J Biol Chem. 273:9323–9329. 1998. View Article : Google Scholar
9	Zhou B, Wu L, Shen K, Zhang J, Lawrence DS and Zhang ZY: Multiple regions of MAP kinase phosphatase 3 are involved in its recognition and activation by ERK2. J Biol Chem. 276:6506–6515. 2001. View Article : Google Scholar : PubMed/NCBI
10	Sridhar SS, Hedley D and Siu LL: Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 4:677–685. 2005. View Article : Google Scholar : PubMed/NCBI
11	Kohno M and Pouyssegur J: Targeting the ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006. View Article : Google Scholar : PubMed/NCBI
12	Furukawa T, Yatsuoka T, Youssef EM, et al: Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer. Cytogenet Cell Genet. 82:156–159. 1998. View Article : Google Scholar : PubMed/NCBI
13	Furukawa T, Sunamura M, Motoi F, Matsuno S and Horii A: Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol. 162:1807–1815. 2003. View Article : Google Scholar : PubMed/NCBI
14	Furukawa T, Fujisaki R, Yoshida Y, et al: Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol. 18:1034–1042. 2005. View Article : Google Scholar
15	Xu S, Furukawa T, Kanai N, Sunamura M and Horii A: Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet. 50:159–167. 2005. View Article : Google Scholar : PubMed/NCBI
16	Okudela K, Yazawa T, Woo T, et al: Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am J Pathol. 175:867–881. 2009. View Article : Google Scholar : PubMed/NCBI
17	Chan DW, Liu VW, Tsao GS, et al: Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis. 29:1742–1750. 2008. View Article : Google Scholar : PubMed/NCBI
18	Croonquist PA, Linden MA, Zhao F and Van Ness BG: Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood. 102:2581–2592. 2003. View Article : Google Scholar : PubMed/NCBI
19	Bloethner S, Chen B, Hemminki K, et al: Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis. 26:1224–1232. 2005. View Article : Google Scholar : PubMed/NCBI
20	Ramnarain DB, Park S, Lee DY, et al: Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res. 66:867–874. 2006. View Article : Google Scholar : PubMed/NCBI
21	Messina S, Frati L, Leonetti C, et al: Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene. 30:3813–3820. 2011. View Article : Google Scholar : PubMed/NCBI
22	Warmka JK, Mauro LJ and Wattenberg EV: Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras. J Biol Chem. 279:33085–33092. 2004. View Article : Google Scholar : PubMed/NCBI
23	Cui Y, Parra I, Zhang M, et al: Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 66:5950–5959. 2006. View Article : Google Scholar : PubMed/NCBI
24	Chiappinelli KB, Rimel BJ, Massad LS and Goodfellow PJ: Infrequent methylation of the DUSP6 phosphatase in endometrial cancer. Gynecol Oncol. 119:146–150. 2010. View Article : Google Scholar : PubMed/NCBI
25	No authors listed. Esophageal cancer: epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol Hepatol. 5:517–526. 2008. View Article : Google Scholar
26	Leung AC, Wong VC, Yang LC, et al: Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. Int J Cancer. 122:587–594. 2008. View Article : Google Scholar
27	Wang Y, Fan H, Zhou B, et al: Fusion of human umbilical cord mesenchymal stem cells with esophageal carcinoma cells inhibits the tumorigenicity of esophageal carcinoma cells. Int J Oncol. 40:370–377. 2012.PubMed/NCBI
28	Han Y, Wei F, Xu X, et al: Establishment and comparative genomic hybridization analysis of human esophageal carcinomas cell line EC9706. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 19:455–457. 2002.(In Chinese).
29	Shimada Y, Imamura M, Wagata T, Yamaguchi N and Tobe T: Characterization of 21 newly established esophageal cancer cell lines. Cancer. 69:277–284. 1992. View Article : Google Scholar : PubMed/NCBI
30	Li LW, Yu XY, Yang Y, Zhang CP, Guo LP and Lu SH: Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer. 125:1505–1513. 2009. View Article : Google Scholar : PubMed/NCBI
31	Li C, Scott DA, Hatch E, Tian X and Mansour SL: Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development. Development. 134:167–176. 2007. View Article : Google Scholar : PubMed/NCBI
32	Furukawa T and Horii A: Molecular pathology of pancreatic cancer: in quest of tumor suppressor genes. Pancreas. 28:253–256. 2004. View Article : Google Scholar : PubMed/NCBI
33	Shimada Y, Sato F, Watanabe G, et al: Loss of fragile histidine triad gene expression is associated with progression of esophageal squamous cell carcinoma, but not with the patient’s prognosis and smoking history. Cancer. 89:5–11. 2000.
34	Zhu YH, Fu L, Chen L, et al: Downregulation of the novel tumor suppressor DIRAS1 predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Res. 73:2298–2309. 2013. View Article : Google Scholar : PubMed/NCBI
35	Baylin SB and Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
36	Feinberg AP, Ohlsson R and Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet. 7:21–33. 2006. View Article : Google Scholar : PubMed/NCBI
37	Wong VC, Chen H, Ko JM, et al: Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J Cancer. 130:83–95. 2012. View Article : Google Scholar : PubMed/NCBI
38	Rössig L, Haendeler J, Hermann C, et al: Nitric oxide down-regulates MKP-3 mRNA levels: involvement in endothelial cell protection from apoptosis. J Biol Chem. 275:25502–25507. 2000.PubMed/NCBI
39	Zhang Z, Kobayashi S, Borczuk AC, et al: Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis. 31:577–586. 2010. View Article : Google Scholar : PubMed/NCBI
40	Le Gall M, Chambard JC, Breittmayer JP, Grall D, Pouyssegur J and Van Obberghen-Schilling E: The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol Biol Cell. 11:1103–1112. 2000.PubMed/NCBI
41	Bonni A, Brunet A, West AE, Datta SR, Takasu MA and Greenberg ME: Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 286:1358–1362. 1999. View Article : Google Scholar : PubMed/NCBI
42	Erhardt P, Schremser EJ and Cooper GM: B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol. 19:5308–5315. 1999.PubMed/NCBI
43	Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI